Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps.
Philippe GevaertStella E LeeRussell A SettipaneMartin WagenmannJérôme MsihidShahid SiddiquiScott NashJuby A Jacob-NaraAsif H KhanSiddhesh KamatChien-Chia ChuangPublished in: Clinical & translational immunology (2023)
Significantly, more patients achieved improvement from moderate-to-severe symptoms to no-to-mild symptoms with dupilumab than placebo, regardless of prior surgery or coexisting asthma. Improvement was observed as early as Week 2 and continued through to Week 52.
Keyphrases
- chronic rhinosinusitis
- end stage renal disease
- atopic dermatitis
- ejection fraction
- minimally invasive
- sleep quality
- chronic kidney disease
- chronic obstructive pulmonary disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- placebo controlled
- early onset
- coronary artery bypass
- lung function
- depressive symptoms
- double blind
- drug induced
- surgical site infection